InvestorsHub Logo
Followers 0
Posts 18
Boards Moderated 0
Alias Born 07/02/2015

Re: None

Friday, 03/04/2022 7:26:40 PM

Friday, March 04, 2022 7:26:40 PM

Post# of 29
“Preferred Recommendation Chances"

The success of this company seems to hinge on getting "ACIP preferred recommendation".

The vaccine seems to be very expensive and difficult to manufacture. $102,000,000 gone in the year before they even started a phase 1 trial. Seems very expensive and too hard to manufacture.

Are there other companies with conjugate vaccines just as good?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PCVX News